Unmet Need
· Ocular infections are quite common, with millions of cases occurring each year. Without proper treatment, infections can lead to serious complications (e.g., blindness).
· The current standard of care requires patients to self-administer eye drops at least 3 times daily to maintain therapeutic concentration levels; in severe cases, administration is as frequently as every hour.
· This treatment strategy is burdensome to patients, but non-compliance can increase infection severity and contributes to antibiotic resistance.
· Therefore, there is a strong need to develop therapeutics that provide sustained antibiotic release, requiring less frequent administration.
Value Proposition
· Single administration required to provide therapeutic benefit.
· Crystalline antibiotic formulation to achieve sustained release.
· Can to be used both prophylactically after ocular surgery and to treat established infections.
Technology Description
· Researchers at Johns Hopkins have developed a crystalline antibiotic formulation that can be delivered with a single subconjunctival injection.
· Microcrystal and nanocrystal antibiotic preparations provide sustained release.
· Preclinical data demonstrates successful treatment and prevention of ocular infection in a rodent model.
Stage of Development
· Pre-clinical proof of concept studies complete
· Pre-clinical safety studies in progress
Publication
N/A
